Gilead Opts In On Multiple Arcus IO Candidates, Setting Up Combo Therapy Plans
Gilead is licensing two anti-TIGIT candidates and a pair of adenosine pathway-targeted drugs. The firms will study various IO combo regimens, possibly including Gilead drugs like Trodelvy.
You may also be interested in...
The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.
Arcus Biosciences has one of the most advanced TIGIT programs, but early data were not strong enough to convince partner Gilead to commit to funding pivotal studies just yet
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.